01—Abstract
Summary
Summary of the 8-K filed November 24, 2025. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) has announced a significant financing event through a Credit and Guaranty Agreement executed on November 19, 2025, detailed in an 8-K filing dated November 24, 2025.
The company has secured a $1.5 billiona credit facility, comprising a $600 million initial term loan and $900 million in delayed draw term loans. This facility provides substantial financial flexibility, with a portion of the delayed draw loans contingent upon achieving key regulatory milestones for its late-stage clinical pipeline, underscoring the importance of its drug development progress. The credit facility matures in November 2030 and is guaranteed by several of Moderna's international subsidiaries, secured by an all-asset collateral grant.
Key financial covenants include a minimum liquidity requirement, which can be eased if the company's market capitalization exceeds $5 billionb, and is subject to an equity cure provision. This financing is crucial for supporting Moderna's ongoing research and development efforts and advancing its pipeline towards commercialization.
02—Key points
Key Highlights
- Moderna secured a $1.5 billion credit facility with Ares Capital Corporation.
- The facility includes a $600 million initial term loan and $900 million in delayed draw term loans.
- A portion of the delayed draw loans ($500 million) is contingent on achieving key regulatory milestones.
- The credit facility has a maturity date of November 24, 2030.
- The loans are guaranteed by specified international subsidiaries and secured by all company assets.
- A minimum liquidity covenant of $500 million (potentially $750 million) is in place, with waivers triggered by a market capitalization exceeding $5 billion.
- The financing is intended to support the company's late-stage clinical pipeline and ongoing operations.
03—Questions
Frequently Asked Questions
What is the total amount of the new credit facility secured by Moderna?
Moderna has secured a $1.5 billion credit facility.
What are the terms of the $1.5 billion credit facility?
The facility consists of a $600 million initial term loan and $900 million available as delayed draw term loans. The delayed draw loans have different availability periods and conditions, with $500 million contingent on achieving key regulatory milestones.
What are the key financial covenants associated with this credit facility?
The agreement includes a minimum liquidity covenant requiring at least $500 million in cash and cash equivalents weekly, which increases to $750 million if over $1 billion is drawn. This covenant is not tested if Moderna's market capitalization exceeds $5 billion and is subject to an equity cure provision.
How will this new credit facility impact Moderna's financial strategy?
This credit facility provides Moderna with significant financial flexibility to fund its late-stage clinical pipeline, including the development and potential commercialization of its mRNA-based therapies, and to support ongoing operational needs.
04—Continue